|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Enrique A. Conterno||CEO & Director||1,31M||N/D||1967|
|Mr. Juan Graham||Chief Financial Officer||377,44k||N/D||1976|
|Dr. Elias Kouchakji||Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance||N/D||N/D||1956|
|Ms. Christine L. Chung||Sr. VP of China Operations||1,01M||N/D||1968|
|Mr. Thane Wettig||Chief Commercial Officer||709,39k||N/D||1965|
|Dr. Mark Eisner M.D., M.P.H.||Chief Medical Officer||1,87M||N/D||1966|
|Dr. Barry A. Berkowitz Ph.D.||Founder||N/D||N/D||N/D|
|Dr. John J. Hunter Ph.D.||Chief Scientific Officer||N/D||N/D||1963|
|Ms. Karen L. Bergman||VP of Investor Relations & Corp. Communications||N/D||N/D||N/D|
|Mr. Michael D. Lowenstein J.D., Ph.D.||Chief Legal Officer||N/D||N/D||N/D|
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
L'ISS Governance QualityScore di FibroGen, Inc. al 31 luglio 2022 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 8; retribuzione: 10.